Viatris

Yahoo Finance • 11 days ago

Viatris rises after a steep seven-day slide

Viatris (NASDAQ:VTRS [https://seekingalpha.com/symbol/VTRS]) rose 2.93% on Wednesday to $9.84, breaking a sharp seven-session decline. Over the past seven trading days, VTRS shed around 9%, with daily losses including a 3.61% drop on Sept... Full story

Yahoo Finance • 13 days ago

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed from the 2020 merger of Mylan and Pfizer’s Upjohn division... Full story

Yahoo Finance • 13 days ago

Explore the top gainers and losers within the S&P500 index in today's session.

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE... Full story

Yahoo Finance • 21 days ago

Nutrien to sell 50% equity position in Profertil

* Nutrien (NYSE:NTR [https://seekingalpha.com/symbol/NTR]) has agreed to sell its 50% stake in Argentina-based urea producer Profertil S.A. to Adecoagro S.A. (NYSE:AGRO [https://seekingalpha.com/symbol/AGRO]) and Asociacion de Cooperativ... Full story

Yahoo Finance • 26 days ago

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

Key Points The "Dogs of the Dow" can uncover steady, high-yield stalwarts, not just temporarily cheap names. Verizon and Chevron face more long-term issues than sudden system shocks. Merck's high yield looks like a classic Dogs idea. 10 s... Full story

Yahoo Finance • last month

Victoria’s Secret Non-GAAP EPS of $0.33 beats by $0.20, revenue of $1.46B beats by $50M

* Victoria’s Secret press release [https://seekingalpha.com/pr/20214304-victoria-s-secret-and-co-reports-second-quarter-2025-results] (NYSE:VSCO [https://seekingalpha.com/symbol/VSCO]): Q2 Non-GAAP EPS of $0.33 beats by $0.20. * Revenu... Full story

Yahoo Finance • last month

Viatris names Andrew Enrietti as chief administrative officer

PITTSBURGH - Viatris Inc. (NASDAQ:VTRS), a global healthcare company with a market capitalization of $12.4 billion and annual revenue of $14.1 billion, has appointed Andrew Enrietti to the newly created position of Chief Administrative and... Full story

Yahoo Finance • last month

David Einhorn's Greenlight Capital adds FLR, VSCO, exits VTRS, among other trades

[Finance: Businessman Holding Financial Analysis on Global Technology Network, Market Insights, Strategic Planning, Investment Opportunities.] Sumedha Lakmal/iStock via Getty Images David Einhorn's Greenlight Capital took new positions in... Full story

Yahoo Finance • 2 months ago

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vi... Full story

Yahoo Finance • 2 months ago

Monday Sector Leaders: Healthcare, Financial

Looking at the sectors faring best as of midday Monday, shares of Healthcare companies are outperforming other sectors, higher by 1.0%. Within the sector, Charles River Laboratories International Inc. (Symbol: CRL) and West Pharmaceutical... Full story

Yahoo Finance • 2 months ago

Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer

[FDA headquarters in Washington DC.] JHVEPhoto Viatris (NASDAQ:VTRS [https://seekingalpha.com/symbol/VTRS]) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic product targeting Venofer markete... Full story

Yahoo Finance • 2 months ago

EpiPen patent expiry opens new era for innovation

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market. Mylan acquired the rights to the injector pen for treating anaphylactic reactions following the $6.7bn acqui... Full story

Yahoo Finance • 2 months ago

Viatris Non-GAAP EPS of $0.62 beats by $0.06, revenue of $3.58B beats by $120M

* Viatris press release [https://seekingalpha.com/pr/20192714-viatris-reports-second-quarter-2025-results-and-reiterates-2025-financial-guidance] (NASDAQ:VTRS [https://seekingalpha.com/symbol/VTRS]): Q2 Non-GAAP EPS of $0.62 beats by $0.... Full story

Yahoo Finance • 2 months ago

Daily Dividend Report: BR,APO,VTRS,L,PAYC

On August 4, 2025, Broadridge's Board of Directors declared a quarterly dividend of $0.975 per share payable on October 2, 2025 to stockholders of record on September 11, 2025. This declaration reflects the Board's approval of an 11% incre... Full story

Yahoo Finance • 2 months ago

Viatris Stock: Analyst Estimates & Ratings

Viatris Inc. (VTRS), headquartered in Canonsburg, Pennsylvania, operates as a healthcare company. With a market cap of $10.3 billion, the company produces medicines for patients across a broad range of major therapeutic areas spanning both... Full story

Yahoo Finance • 2 months ago

Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health

Company Logo Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor ty... Full story

Yahoo Finance • 2 months ago

[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.... Full story

Yahoo Finance • 2 months ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sandra Leung to its Board of Directors, e... Full story

Yahoo Finance • 2 months ago

US FDA advisers vote against Otsuka's PTSD combination treatment

(Reuters) -The U.S. Food and Drug Administration’s panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma’s drug when used in combination with Viatris’ Zoloft for the treatment of adults with PTSD. The panel v... Full story

Yahoo Finance • 2 months ago

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss

Investing.com - Viatris Inc (NASDAQ:VTRS), a prominent player in the pharmaceuticals industry with a market cap of $10.45 billion, maintained its Neutral rating and $10.00 price target at Goldman Sachs following disappointing clinical tria... Full story